Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G

被引:0
|
作者
William R Lovallo
Mary-Anne Enoch
Ashley Acheson
Andrew J Cohoon
Kristen H Sorocco
Colin A Hodgkinson
Andrea S Vincent
David C Glahn
David Goldman
机构
[1] VA Medical Center,Department of Psychiatry and Behavioral Sciences
[2] University of Oklahoma Health Sciences Center,Department of Psychiatry
[3] Laboratory of Neurogenetics,Donald W. Reynolds Department of Geriatric Medicine
[4] NIH,Department of Psychiatry
[5] NIAAA,undefined
[6] University of Texas Health Sciences Center at San Antonio,undefined
[7] Research Imaging Institute,undefined
[8] UTHSCSA,undefined
[9] OUHSC,undefined
[10] Cognitive Science Research Center,undefined
[11] University of Oklahoma,undefined
[12] Olin Neuropsychiatry Research Center,undefined
[13] Institute of Living,undefined
[14] Hartford Hospital,undefined
[15] Yale University School of Medicine,undefined
来源
Neuropsychopharmacology | 2015年 / 40卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Differences in stress reactivity may affect long-term health outcomes, but there is little information on how these differences arise. The stress axis is regulated by, in part, the endogenous opioid, beta-endorphin, acting on mu-opioid receptors. Persons carrying one or two copies of the G allele of the mu-opioid receptor gene (OPRM1 A118G) may have higher receptor binding for beta-endorphin compared with AA homozygotes that may contribute to individual differences in cortisol reactivity to stress, leading to a relative blunting of cortisol stress reactivity in G allele genotypes. We measured cortisol in 251 young adults (69 GA/GG vs 182 AA genotypes) exposed to mental arithmetic plus public speaking stress relative to a resting control day. Women had smaller cortisol responses than men (F=10.2, p=0.002), and women with GA or GG genotypes (N=39) had an absence of cortisol response relative to AA carriers (N=110) (F=18.4, p<0.0001). Male genotypes had no such difference in response (F=0.29). Cortisol response following mu-opioid receptor blockade using naltrexone in 119 of these subjects unmasked a greater tonic opioid inhibition of cortisol secretion in women (N=64), consistent with their blunted stress reactivity. Compared with men, women may have cortisol stress responses that are more heavily regulated by endogenous opioid mechanisms, and the OPRM1 GA/GG genotypes may affect females differentially relative to males. Diminished cortisol responses to stress may have consequences for health behaviors in women with GA/GG genotypes.
引用
收藏
页码:2546 / 2554
页数:8
相关论文
共 50 条
  • [31] The Mu-Opioid Receptor Gene Polymorphism (A118G) Alters HPA Axis Activation Induced by Opioid Receptor Blockade
    Gary S Wand
    Mary McCaul
    Xioaju Yang
    Joanna Reynolds
    Deidre Gotjen
    Shing Lee
    Ahmed Ali
    Neuropsychopharmacology, 2002, 26 : 106 - 114
  • [32] μ-Opioid Receptor Gene (OPRM1) Polymorphism A118G: Lack of Association in Finnish Populations with Alcohol Dependence or Alcohol Consumption
    Rouvinen-Lagerstrom, Noora
    Lahti, Jari
    Alho, Hannu
    Kovanen, Leena
    Aalto, Mauri
    Partonen, Timo
    Silander, Kaisa
    Sinclair, David
    Raikkonen, Katri
    Eriksson, Johan G.
    Palotie, Aarno
    Koskinen, Seppo
    Saarikoski, Sirkku T.
    ALCOHOL AND ALCOHOLISM, 2013, 48 (05): : 519 - 525
  • [33] The Mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade
    Wand, GS
    McCaul, M
    Yang, XJ
    Reynolds, J
    Gotjen, D
    Lee, S
    Ali, A
    NEUROPSYCHOPHARMACOLOGY, 2002, 26 (01) : 106 - 114
  • [34] Associations of OPRM1 A118G Gene Polymorphism with Pain Sensitivity and Opioid Dosage of Patients with Postherpetic Neuralgia
    Fu, Qiang
    Qin, Liyuan
    Li, Quanbo
    INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2022, 22 (02) : 86 - 92
  • [35] Allele frequency and genotype distribution of the opioid receptor μ-1 (OPRM1) A118G polymorphism in the Western Saudi population
    Bagher, Amina M.
    Hareeri, Rawan H.
    JOURNAL OF APPLIED BIOMEDICINE, 2023, 21 (03) : 160 - 165
  • [36] Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients
    Marini, Valeria
    Fucile, Carmen
    Zuccoli, Maria Laura
    Testino, Giovanni
    Sumberaz, Alessandro
    Robbiano, Luigi
    Martelli, Antonietta
    Mattioli, Francesca
    ADDICTIVE BEHAVIORS, 2013, 38 (03) : 1669 - 1671
  • [37] Associations of the A118G OPRM1 polymorphism with sociotropy and interpersonal sensitivity
    Suzuki, Akihito
    Shirata, Toshinori
    Noto, Keisuke
    Matsumoto, Yoshihiko
    Muraosa, Haruka
    Abe, Mio
    Goto, Kaoru
    Otani, Koichi
    BRAIN AND BEHAVIOR, 2022, 12 (07):
  • [38] Mu-opioid receptor binding affinity to fentanyl is affected by sex but not by A118G polymorphism
    Landau, R.
    Charvet, I.
    Blouin, J.
    ANESTHESIOLOGY, 2007, 106 (05) : B18 - B18
  • [39] Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype
    Hisham Ziauddeen
    Liam J Nestor
    Naresh Subramaniam
    Chris Dodds
    Pradeep J Nathan
    Sam R Miller
    Bhopinder K Sarai
    Kay Maltby
    Disala Fernando
    Liling Warren
    Louise K Hosking
    Dawn Waterworth
    Anna Korzeniowska
    Beta Win
    Duncan B Richards
    Lakshmi Vasist Johnson
    Paul C Fletcher
    Edward T Bullmore
    Neuropsychopharmacology, 2016, 41 : 2647 - 2657
  • [40] Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype
    Ziauddeen, Hisham
    Nestor, Liam J.
    Subramaniam, Naresh
    Dodds, Chris
    Nathan, Pradeep J.
    Miller, Sam R.
    Sarai, Bhopinder K.
    Maltby, Kay
    Fernando, Disala
    Warren, Liling
    Hosking, Louise K.
    Waterworth, Dawn
    Korzeniowska, Anna
    Win, Beta
    Richards, Duncan B.
    Johnson, Lakshmi Vasist
    Fletcher, Paul C.
    Bullmore, Edward T.
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 (11) : 2647 - 2657